ONWARD Medical Schedules First-Half 2026 Results Amid ARC-IM Development Push
Event summary
- ONWARD Medical to release first-half 2026 financial results on September 9, 2026.
- CEO Dave Marver to host webcast with comprehensive business update at 2:00 p.m. CEST / 8:00 a.m. EDT.
- Company has received 10 Breakthrough Device Designations from the FDA for its ARC Therapy.
- ARC-EX® System commercially available in the US and Europe; ARC-IM® remains investigational.
The big picture
ONWARD Medical's upcoming earnings release comes as the company balances commercializing its ARC-EX system with advancing its investigational ARC-IM technology. The strategic tension lies in managing near-term revenue growth against long-term innovation, particularly in a competitive neurotechnology landscape where regulatory milestones are critical. The company's 10 FDA Breakthrough Device Designations underscore its technological edge, but execution will determine its market positioning.
What we're watching
- Regulatory Progress
- The pace at which ARC-IM gains regulatory approvals will determine commercialization timelines.
- Revenue Diversification
- Whether ARC-EX can sustain growth while ARC-IM remains in development.
- Competitive Positioning
- How ONWARD Medical differentiates itself in the neurotechnology space amid increasing competition.
Related topics